The Auscann Group Holdings Ltd (ASX: AC8) share price was down 4% to $1.68 on Friday, after the stock had climbed 25% higher during the week.
While the main driver of the price surge was the announcement that the company received an import permit to source medicinal cannabis products from Canadian company Canopy Growth Corporation, on Thursday Auscann released a report summarising progress made in the March 2018 quarter.
Auscann and its partner Tasmanian Alkaloid expect to plant their first Australian crop this year, and to have products available by early 2019. Auscann signed an agreement with Australian Pharmaceutical Industries Ltd (ASX: API) for the domestic distribution of its products, but the company is also looking at export markets.
In fact, at the beginning of January, Auscann’s share price skyrocketed on the news that the federal government would permit the export of cannabinoid medicines from Australia.
In the meantime, Chilean authorities have granted patients immediate access to medicinal cannabis. Auscann operates in Chile through Dayacann, a joint venture with the local Fundación Daya.
Auscann spent $1.5 million during the quarter, and $400,000 in R&D. This leaves a $12 million cash balance, enough to continue operations while looking forward to the first sales.
Follow the free link below to find out about the other innovative companies that are poised to outperform the market in 2018.
These 3 stocks could be the next big movers in 2020
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.
*Returns as of 6/8/2020
Motley Fool contributor Tommaso Autorino has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
- Why the Freelancer Ltd (ASX:FLN) share price dropped 16% today – July 31, 2018 3:05pm
- The Syrah Resources Ltd (ASX:SYR) share price falls 7% on guidance downgrade – July 30, 2018 1:01pm
- AMP Limited (ASX:AMP) shares slide to new multi-year low on earnings downgrade – July 29, 2018 6:44pm